BD Achieves Breakthrough in Clinical Trial of GalaFLEX LITE™ Scaffold for Breast Implant Revisions

BD (Becton, Dickinson and Company) has commenced patient treatment in an Investigational Device Exemption (IDE) clinical trial. The trial aims to support BD’s application for Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in reducing the recurrence of capsular contracture (CC) during breast revision surgery.

Breast implant procedures are among the most frequently performed plastic surgeries in the United States. However, capsular contracture is a common complication, occurring in approximately 10% to 20% of cases. This condition results in the formation of unusually firm scar tissue around the implant, leading to pain and anatomical displacement. In advanced cases, surgical intervention is required, and traditional revision techniques have shown recurrence rates as high as 54%.

The GalaFLEX LITE™ Scaffold is designed to provide structural support during the wound healing process. Made from Poly-4-Hydroxybutyrate (P4HB), a fully absorbable polymer, it has been used clinically for over a decade in procedures such as hernia repair and plastic surgery where soft tissue reinforcement is required.

At least 250 patients will be recruited across 40 sites to evaluate the safety and effectiveness of GalaFLEX LITE™ Scaffold in reducing CC recurrence. BD continues to prioritise scientific research and patient safety, ensuring ongoing collaboration with the FDA to enhance women’s healthcare solutions.

The findings from this trial will provide essential data to support regulatory approval and further advancements in breast surgery care.